These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 17714589)
1. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. Park JY; Schutzer WE; Lindsley JN; Bagby SP; Oyama TT; Anderson S; Weiss RH BMC Nephrol; 2007 Aug; 8():12. PubMed ID: 17714589 [TBL] [Abstract][Full Text] [Related]
2. Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease. Park JY; Park SH; Weiss RH Am J Nephrol; 2009; 29(6):509-15. PubMed ID: 19066425 [TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation. Liu C; Zhang Y; Yuan L; Fu L; Mei C Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113 [TBL] [Abstract][Full Text] [Related]
4. Mutant polycystin-2 induces proliferation in primary rat tubular epithelial cells in a STAT-1/p21-independent fashion accompanied instead by alterations in expression of p57KIP2 and Cdk2. Felekkis KN; Koupepidou P; Kastanos E; Witzgall R; Bai CX; Li L; Tsiokas L; Gretz N; Deltas C BMC Nephrol; 2008 Aug; 9():10. PubMed ID: 18721488 [TBL] [Abstract][Full Text] [Related]
5. Role of keratinocyte growth factor in the pathogenesis of autosomal dominant polycystic kidney disease. Mei C; Mao Z; Shen X; Wang W; Dai B; Tang B; Wu Y; Cao Y; Zhang S; Zhao H; Sun T Nephrol Dial Transplant; 2005 Nov; 20(11):2368-75. PubMed ID: 16141466 [TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells. Liu Y; Dai B; Fu L; Jia J; Mei C Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):523-30. PubMed ID: 20210794 [TBL] [Abstract][Full Text] [Related]
7. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Bukanov NO; Smith LA; Klinger KW; Ledbetter SR; Ibraghimov-Beskrovnaya O Nature; 2006 Dec; 444(7121):949-52. PubMed ID: 17122773 [TBL] [Abstract][Full Text] [Related]
8. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Bukanov NO; Moreno SE; Natoli TA; Rogers KA; Smith LA; Ledbetter SR; Oumata N; Galons H; Meijer L; Ibraghimov-Beskrovnaya O Cell Cycle; 2012 Nov; 11(21):4040-6. PubMed ID: 23032260 [TBL] [Abstract][Full Text] [Related]
9. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. Xu T; Wang NS; Fu LL; Ye CY; Yu SQ; Mei CL Mol Biol Rep; 2012 Jul; 39(7):7743-53. PubMed ID: 22415852 [TBL] [Abstract][Full Text] [Related]
10. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. Nishio S; Hatano M; Nagata M; Horie S; Koike T; Tokuhisa T; Mochizuki T J Clin Invest; 2005 Apr; 115(4):910-8. PubMed ID: 15761494 [TBL] [Abstract][Full Text] [Related]
11. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708 [TBL] [Abstract][Full Text] [Related]
13. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells. Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483 [TBL] [Abstract][Full Text] [Related]
14. Cell Proliferation and Apoptosis in ADPKD. Lee EJ Adv Exp Med Biol; 2016; 933():25-34. PubMed ID: 27730432 [TBL] [Abstract][Full Text] [Related]
15. TNFα signaling regulates cystic epithelial cell proliferation through Akt/mTOR and ERK/MAPK/Cdk2 mediated Id2 signaling. Zhou JX; Fan LX; Li X; Calvet JP; Li X PLoS One; 2015; 10(6):e0131043. PubMed ID: 26110849 [TBL] [Abstract][Full Text] [Related]
16. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis. Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683 [TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia. Wang W; Mei C; Tang B; Zhao H; Xu C; Li Z; Shen X; Fu W; Dai B Nephrol Dial Transplant; 2006 May; 21(5):1278-88. PubMed ID: 16421164 [TBL] [Abstract][Full Text] [Related]
18. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels. Tan M; Wettersten HI; Chu K; Huso DL; Watnick T; Friedlander S; Landesman Y; Weiss RH Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1179-86. PubMed ID: 25234309 [TBL] [Abstract][Full Text] [Related]
19. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. Chen L; Zhou X; Fan LX; Yao Y; Swenson-Fields KI; Gadjeva M; Wallace DP; Peters DJ; Yu A; Grantham JJ; Li X J Clin Invest; 2015 Jun; 125(6):2399-412. PubMed ID: 25961459 [TBL] [Abstract][Full Text] [Related]